ClinicalTrials.gov
ClinicalTrials.gov Menu

An 8-week Study to Evaluate Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients With Dry Eye

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03019627
Recruitment Status : Recruiting
First Posted : January 12, 2017
Last Update Posted : February 3, 2017
Sponsor:
Information provided by (Responsible Party):
Dompé Farmaceutici S.p.A

Brief Summary:
The phase II study is a single-center, randomized, double-masked, parallel-arm, vehicle-controlled trial, designed to evaluate the safety and efficacy of Recombinant Human Nerve Growth Factor (rhNGF) eye drops at 20 μg/ml concentration administered six times daily for 8 weeks in patients with dry eye.

Condition or disease Intervention/treatment Phase
Dry Eye Drug: NGF Other: Vehicle Phase 2

Detailed Description:
The proposed phase II study is a single-center, randomized, double-masked, parallel-arm, vehicle-controlled trial, designed to evaluate the safety and efficacy of Recombinant Human Nerve Growth Factor (rhNGF) eye drops at 20 μg/ml concentration administered six times daily for 8 weeks in patients with dry eye. After confirmation of inclusion and exclusion criteria all eligible patients will be randomized at 2:1 ratio to rhNGF or vehicle control treatment with 8 weeks of study treatments administration with 4 weeks Follow-up.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: An 8-week, Phase II, Single-center, Randomized, Double-masked, Vehicle-controlled, Parallel-group Study With 4 Weeks of Follow-up to Evaluate Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients With Dry Eye
Study Start Date : January 2017
Estimated Primary Completion Date : August 2017
Estimated Study Completion Date : September 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Recombinant Human Nerve Growth Factor (rhNGF)
Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
Drug: NGF
Eye Drop 20 μg/mL

Placebo Comparator: Vehicle
vehicle eye drops six times daily
Other: Vehicle
Vehicle Eye Drop




Primary Outcome Measures :
  1. Symptom Assessment iN Dry Eye (SANDE) scores [ Time Frame: week 8 ]
    Change from baseline with Last observation carried forward (LOCF) imputation


Secondary Outcome Measures :
  1. SANDE scores [ Time Frame: week 4 ]
    Change from baseline without imputation

  2. SANDE scores [ Time Frame: week 8 ]
    Change from baseline without imputation

  3. Cornea vital staining [ Time Frame: week 8 ]
    Changes in Nation Eye Institute (NEI) scale

  4. conjunctival vital staining [ Time Frame: week 8 ]
    Changes in Nation Eye Institute (NEI) scale



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients (male or female) must be ≥ 18 years of age.
  2. Patients must be diagnosed with any type of dry eye (e.g. Meibomian Gland Dysfunction, Blepharitis, Keratoconjunctivitis sicca etc) at least 3 months before enrollment.
  3. Patients must present dry eye pathology characterized by the following clinical features:

    1. Corneal and/or conjunctival staining with fluorescein and lissamine green using National Eye Institute (NEI) grading system > 3
    2. Mean Symptom Assessment in Dry Eye (SANDE) questionnaire ≥30
    3. Schirmer test without anesthesia < 10 mm/5 minutes and/or tear film break-up time (TFBUT) < 10 seconds in the study eye
  4. The same eye (study eye) must fulfill all the above criteria.
  5. Patients must have best corrected distance visual acuity (BCDVA) score of ≥ 0.1 decimal units in both eyes at the time of study enrollment.
  6. Female patients must have negative pregnancy test if at childbirth potential.
  7. Only patients who satisfy all requirements for informed consent may be included in the study. Written Informed Consent must be obtained before the initiation of any study specific procedures.
  8. Patients must have the ability and willingness to comply with study procedures.

Exclusion Criteria:

  1. Best corrected distance visual acuity (BCDVA) score of < 0.1 decimal units in either eye.
  2. Evidence of an active ocular infection in either eye.
  3. Presence or history of any ocular disorder or condition, including ocular surgery, trauma, or disease that could possibly interfere with the interpretation of study results in the opinion of the Investigator.
  4. Intraocular inflammation defined as Tyndall score >0.
  5. Active or recent diagnosis of malignancy (i.e., currently under chemo/radiotherapy).
  6. Systemic disease not stabilized within 1 month before baseline visit (e.g., uncontrolled diabetes; thyroid malfunction) or judged by the Investigator to be incompatible with the study (e.g., current systemic infections) or with a condition incompatible with the frequent assessment required by the study.
  7. Patients who have had a serious adverse reaction or significant hypersensitivity to any drug or chemically related compounds, or had a clinically significant allergy to drugs, foods, amide local anesthetics, or other materials, including commercial artificial tears containing carboxymethylcellulose (CMC) (in the opinion of the Investigator).
  8. Use of topical cyclosporine, topical corticosteroids, or any other topical medication for the treatment of dry eye in either eye until the day of study enrollment.
  9. Contact lenses or punctal plug use during the study (previous use not an exclusion criteria, but must be discontinued at the baseline visit.
  10. An anticipated need of additional systemic treatments for dry eye during the study (all prior treatment must be continued for the entire duration of the study).
  11. Females of childbearing potential (those who are not surgically sterilized or postmenopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:

    1. are currently pregnant or,
    2. have a positive result at the urine pregnancy test (Baseline/Day 0) or,
    3. intend to become pregnant during the study treatment period or,
    4. are breast-feeding or,
    5. are not willing to use highly effective birth control measures, such as: hormonal contraceptives - oral, implanted, transdermal, or injected - and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or a intrauterine device (IUD) - during the entire course of and 30 days after the study treatment periods.
  12. History of drug addiction or alcohol abuse.
  13. Any prior ocular surgery (including refractive palpebral and cataract surgery) if within 90 days before the screening visit.
  14. Participation in a clinical trial with a new active substance during the past 30 days.
  15. Participation in another clinical trial study at the same time as the present study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03019627


Contacts
Contact: Flavio Mantelli, MD, PhD +39 02 583831

Locations
United States, Pennsylvania
Penn Dry Eye and Ocular Surface Center,University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Giacomina Massaro Giordano, MD       Giacomina.Massaro-Giordano@uphs.upenn.edu   
Sponsors and Collaborators
Dompé Farmaceutici S.p.A
Investigators
Principal Investigator: Giacomina Massaro Giordano, MD Penn Dry Eye and Ocular Surface Center,University of Pennsylvania,Scheie Eye Institute

Responsible Party: Dompé Farmaceutici S.p.A
ClinicalTrials.gov Identifier: NCT03019627     History of Changes
Other Study ID Numbers: NGF0216
First Posted: January 12, 2017    Key Record Dates
Last Update Posted: February 3, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Conjunctivitis
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Keratoconjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Mitogens
Ophthalmic Solutions
Tetrahydrozoline
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmaceutical Solutions
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nasal Decongestants
Vasoconstrictor Agents
Respiratory System Agents